CoChat

Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer

Open access
Dembinski, Jennifer L., Wilson, Shanna M., Spaeth, Erika L., Studeny, Matus, Zompetta, Claudia, Samudio, Ismael, Roby, Katherine, Andreeff, Michael, Marini, Frank C. · 2013 · Cytotherapy
Cited by 77

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Many ovarian cancers originate from ovarian surface epithelium, where they develop from cysts intermixed with stroma. The stromal layer is critical to the progression and survival of the neoplasm and consequently is recruited into the tumor microenvironment. Using both syngenic mouse tumors (ID8-R), and human xenograft (OVCAR3, SKOV3) tumor models, we first confirmed intraperitoneally-circulating MSC could target, preferentially engraft and differentiate into α-SMA+ myofibroblasts, suggesting their role as “reactive stroma” in ovarian carcinoma development and confirming their potential as a targeted delivery vehicle for the intratumoral production of interferon-beta (IFNβ). Then, mice with ovarian carcinomas received weekly IP injections of IFNβ expressing MSC, resulting in complete eradication of tumors in 70% of treated OVCAR3 mice (P = 0.004) and an increased survival of treated SKOV3 mice compared with controls (P = 0.01). Similar tumor growth control was observed using murine IFNβ delivered by murine MSC in ID8-R ovarian carcinoma. As a potential mechanism of tumor killing, MSC produced IFNβ induced caspase-dependent tumor cell apoptosis. Our results demonstrate that ovarian carcinoma engraft MSC to participate in myofibrovascular networks and that IFNβ produced by MSC intratumorally modulates tumor kinetics, resulting in prolonged survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcyt.2012.10.003

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 35

  1. Kenny, 2008, The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin, J Clin Invest, 118, 1367, 10.1172/JCI33775 · DOI · Paper page
  2. Ghahremani, 1999, Etiology of ovarian cancer: a proposed mechanism, Med Hypotheses, 52, 23, 10.1054/mehy.1997.0620 · doi:10.1054/mehy.1997.0620
  3. Prockop, 1997, Marrow stromal cells as stem cells for nonhematopoietic tissues, Science, 276, 71, 10.1126/science.276.5309.71 · DOI · Paper page
  4. Pittenger, 1999, Multilineage potential of adult human mesenchymal stem cells, Science, 284, 143, 10.1126/science.284.5411.143 · DOI · Paper page
  5. Dvorak, 1986, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing, N Engl J Med, 315, 1650, 10.1056/NEJM198612253152606 · DOI · Paper page
  6. Xu, 2010, Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro, Oncol Rep, 23, 1561, 10.3892/or_00000796 · DOI
  7. Coffelt, 2009, The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells, Proc Natl Acad Sci USA, 106, 3806, 10.1073/pnas.0900244106 · DOI · Paper page
  8. Studeny, 2002, Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors, Cancer Res, 62, 3603
  9. Studeny, 2004, Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents, J Natl Cancer Inst, 96, 1593, 10.1093/jnci/djh299 · DOI · Paper page
  10. Studeny, 2001, Bone marrow derived mesenchymal stem cells serve as precursors for stromal fibroblasts in malignant tumors and show potential for cancer therapy, Blood, 98
  11. Hu, 2011, Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice, Biotechnol Appl Biochem, 58, 397, 10.1002/bab.63 · DOI
  12. Hata, 2010, Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas, Neurosurgery, 66, 144, 10.1227/01.NEU.0000363149.58885.2E · DOI · Paper page
  13. Wong, 1989, Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines, Int J Cancer, 43, 526, 10.1002/ijc.2910430331 · DOI
  14. Johns, 1992, Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β, J Natl Cancer Inst, 84, 1185, 10.1093/jnci/84.15.1185 · DOI
  15. Chawla-Sarkar, 2001, Preferential induction of apoptosis by interferon (IFN)-β compared with IFN-α2: correlation with TRAIL/Apo2L induction in melanoma cell lines, ClinCancer Res, 7, 1821
  16. Zhang, 1999, Induction of multiple programmed cell death pathways by IFN-β in human non-small-cell lung cancer cell lines, ExpCell Res, 247, 133
  17. Rambaldi, 1985, Intraperitoneal administration of interferon β in ovarian cancer patients, Cancer, 56, 294, 10.1002/1097-0142(19850715)56:2<294::AID-CNCR2820560216>3.0.CO;2-K · doi:10.1002/1097-0142(19850715)56:2<294::aid-cncr2820560216>3.0.co;2-k
  18. Kardamakis, 1991, Interferons in the treatment of malignancies, In Vivo, 5, 589
  19. Cappelli, 1992, The locoregional treatment of neoplastic ascites with interferon-beta, Recenti Prog Med, 83, 82
  20. Einhorn, 1996, Why do so many cancer patients fail to respond to interferon therapy?, J Interferon Cytokine Res, 16, 275, 10.1089/jir.1996.16.275 · DOI
  21. Buchwalder, 2000, Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers, JInterferon Cytokine Res, 20, 857, 10.1089/10799900050163226 · DOI
  22. Salmon, 1996, Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers, J Interferon Cytokine Res, 16, 759, 10.1089/jir.1996.16.759 · DOI · Paper page
  23. Johns, 1990, Pharmacokinetics, tissue distribution, and cell localization of [35S]methionine-labeled recombinant human and murine α interferons in mice, Cancer Res, 50, 4718
  24. Pan, 2005, Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response, J Cancer Res Clin Oncol, 131, 468, 10.1007/s00432-004-0651-y · doi:10.1007/s00432-004-0651-y
  25. Streck, 2005, Adeno-associated virus vector-mediated systemic delivery of IFN-β combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models, Clin Cancer Res, 11, 6020, 10.1158/1078-0432.CCR-05-0502 · DOI · Paper page
  26. Yotnda, 2004, Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses, Hum Gene Ther, 15, 1229, 10.1089/hum.2004.15.1229 · doi:10.1089/hum.2004.15.1229
  27. Odaka, 2001, Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity, Cancer Res, 61, 6201
  28. François, 2006, Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage, Stem Cells, 24, 1020, 10.1634/stemcells.2005-0260 · DOI · Paper page
  29. Saidi, 2006, Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines, Am J Surg, 191, 358, 10.1016/j.amjsurg.2005.10.037 · DOI
  30. Morrison, 2005, Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma, Biochem J, 385, 595, 10.1042/BJ20040971 · DOI
  31. Fulda, 2006, 5-Aza-2′-deoxycytidine and IFN-γ cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8, Oncogene, 25, 5125, 10.1038/sj.onc.1209518 · DOI
  32. Gómez-Benito, 2005, Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-α in human myeloma cells, FEBS Lett, 579, 6217, 10.1016/j.febslet.2005.10.007 · doi:10.1016/j.febslet.2005.10.007
  33. De Feudis, 1997, DDP-induced cytotoxicity is net influenced by p53 in nine human ovarian cancer cell lines with different p53 status, Br J Cancer, 76, 474, 10.1038/bjc.1997.412 · doi:10.1038/bjc.1997.412
  34. Matuskova, 2010, HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells, Cancer Lett, 290, 58, 10.1016/j.canlet.2009.08.028 · DOI · Paper page
  35. Sonabend, 2008, Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma, Stem Cells, 26, 831, 10.1634/stemcells.2007-0758 · DOI · Paper page

Cited by

See all 77

Metadata

Authors
Dembinski, J. L., Wilson, S. M., Spaeth, E. L., Studeny, M., Zompetta, C., Samudio, I., Roby, K., Andreeff, M., & Marini, F. C.
Venue
Cytotherapy
Publisher
Elsevier BV
Published
2013-01
Volume
15
Issue
1
Pages
20-32.e2
ISSN
1465-3249 (ISSN-L)
OpenAlex
W2052489552
Cited by
77
References
8
FWCI
3.70
Type
journal article
Language
en
Open access
bronze
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Cancer Institute (CA-1094551, Ca-116199, RC1CA146381, P50CA083639, R01CA109451, R01NS06994, CA-55164, CA-16672, CA-49639)
  • Susan G. Komen Breast Cancer Foundation (BC083397)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. https://app.cochat.ai/papers/10.1016/j.jcyt.2012.10.003
The paper
Dembinski, J. L., Wilson, S. M., Spaeth, E. L., Studeny, M., Zompetta, C., Samudio, I., Roby, K., Andreeff, M., & Marini, F. C. (2013). Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy. https://doi.org/10.1016/j.jcyt.2012.10.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.